SCHEMBL30890377

SCHEMBL30890377

CC(C)(C)OC(=O)N1C[C@@]2(C[C@H]1C(N)=O)Oc1ccccc1CNC2=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.35
▸ SIRT2 Q8IXJ6 1/20 0.34
▸ SIRT1 Q96EB6 1/20 0.34
▸ NR1H2 P55055 3/20 0.33
▸ RXRA P19793 2/20 0.33
▸ NR1H3 Q13133 2/20 0.33
▸ KDM1A O60341 2/20 0.33
▸ EPHX2 P34913 2/20 0.32
▸ HTRA1 Q92743 1/20 0.32
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ OPRL1 P41146 1/20 0.32
▸ UCHL1 P09936 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ NAMPT P43490 1/20 0.31
▸ PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30890482 0.86 POLB (0.40) MAPK1SIRT2SIRT1NR1H2RXRA
SCHEMBL30992227 0.86 POLB (0.34) SIRT2SIRT1NR1H2RXRANR1H3
SCHEMBL27244855 0.85 PTK2B (0.32) SIRT1EPHX2
SCHEMBL30890451 0.80 OPRM1 (0.45) MAPK1NR1H2RXRANR1H3KDM1A
SCHEMBL27245104 0.80 OPRM1 (0.45) MAPK1NR1H2RXRANR1H3KDM1A
SCHEMBL30890677 0.80 OTUD7B (0.43) MAPK1NR1H2RXRANR1H3KDM1A
SCHEMBL30890744 0.77 AKR1B1 (0.35) NR1H2RXRANR1H3
SCHEMBL30890658 0.77 GRM5 (0.33) KDM1A
SCHEMBL30992283 0.77 CCNB2 (0.36) NR1H2RXRANR1H3IDO1
SCHEMBL30890749 0.77 NR1H2 (0.42) MAPK1NR1H2RXRANR1H3PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
US-20240199647-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-20 — — US disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199647-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 MAPK1 1561/4885SIRT2 2541/4885SIRT1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback